A study conducted in a total of 3837 BC patients, using an xCell-gene-signature-based method on whole tumor gene expression data, demonstrated a high CD8 score in TNBCs that was associated with high tumor immune cytotoxic activity, high immunoreactivity, and better survival. This evidence concerns the gene CD8A and breast cancer.